EZH2 is aberrantly expressed in numerous cancers, including leukemia, pancreatic ductal adenocarcinoma, and hepatocellular carcinoma, and there are now many pre-clinical studies reporting the inhibitory effects of DZNep on tumor growth.54, 55 Treatment of cells with DZNep results in depletion of EZH2 and, as such, this effect and the associated loss of the H3K27me3 mark is considered to be its major mechanism of anti-tumor activity. This evidence concerns the gene EZH2 and hepatocellular carcinoma.